pharmacyte.com - PMCB Company profit before taxes, interest and amortization

Brandmark of pharmacyte.com (PMCB)

Risks for PharmaCyte Biotech (PMCB) are linked to regulatory delays and the threat of liquidity shortages. Cash operating profit before deductions clearly confirms these challenges, while the 0.00 level records fresh values. The stability of biomaterial supplies via backup capacities supports profitability, and the innovative Cell-in-a-Box system opens prospects for diabetes and oncology therapies within the R&D stage.

PharmaCyte Biotech (PMCB) Profit before payment of interest, taxes and amortization: for the period 11/23/2025 - 11/10/2026

PharmaCyte Biotech, Inc. (PMCB) - metric breakdowns and financial figures

- stock value and consensus price forecast:
Market Chart PharmaCyte Biotech Inc.|PMCB - Consensus Target
- issuer market value details:
Market Value PharmaCyte Biotech|PMCB - Total Company Value
- issuer book value statistics:
Net Asset Value per Share PharmaCyte Biotech|PMCB - Company Book Value|Market Cap to Net Assets Ratio pharmacyte.com|PMCB - Company Total Assets
- debt level and financial liquidity data:
Total Debt to Capital PharmaCyte Biotech|PMCB - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio PharmaCyte Biotech Inc.|PMCB - Company Aggregate Debts|Debt to Net Assets Ratio PharmaCyte Biotech|PMCB - Company Long-Term Debt|Current Liabilities PharmaCyte Biotech|Intermediate Coverage Ratio pharmacyte.com
- earnings and market multiples details:
PMCB - Net Profit|Projected Future Earnings PharmaCyte Biotech|PMCB - Price to Earnings Ratio|Future Price to Earnings Multiple PharmaCyte Biotech Inc.|PMCB - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio PharmaCyte Biotech|PMCB - Operating profit EBITDA|Net earnings per share (EPS TTM) PharmaCyte Biotech|PMCB - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months pharmacyte.com|PMCB - Net earnings per share growth this year|Expected net earnings per share growth next year PharmaCyte Biotech
Summary company analytics:PharmaCyte Biotech
Original product of PharmaCyte

For PharmaCyte Biotech (PMCB), the absolute EBITDA level serves as an indicator of the ability of biopolymer cell encapsulation technologies to generate real cash flow from core operations. This metric measures the business's operating efficiency before depreciation and taxes, allowing investors to assess the company's fundamental stability during the diversification of cancer and diabetes treatments, independent of debt load.

Competitors of PharmaCyte Biotech (PMCB)

Operating income before deduction of amortization TriSalus Corp (TLSI)|RNXT: Operating profit before deduction of amortization